Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.

BMJ · 2025 · PMC12723525 · PMID 41436191

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

Moreover, exploratory stage stratified analyses showed a numerical trend towards greater absolute benefit in stage II/III disease than in stage I disease (hazard ratio 0.61 for stage II/III versus 0.76 for stage I), but the test for interaction between stage (I versus II/III) and carboplatin effect was not significant (P for interaction=0.63).

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.